CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

Rhea-AI Summary

CG Oncology (NASDAQ: CGON) will participate in the AUA 2026 Annual Meeting in Washington, D.C., on May 15–18, 2026. The company will present first results from its CORE-008 Cohort CX Phase 2 trial in high-risk BCG-exposed and BCG-unresponsive NMIBC.

CG Oncology will also exhibit at booth #3051 and support CG-SUO-CTC NMIBC Research Fellowship presentations highlighting novel research in non-muscle invasive bladder cancer.

Argus May 12 session

+3.97% close to close 1.8x rel. volume Open Argus

Details

News Market Reaction – CGON

On May 12, the first trading day after this news, CGON closed 3.97% above the previous close. That session’s volume was 1.8x the stock’s average daily volume.

Data tracked by StockTitan Argus for the May 12 session.

Key Figures

Q1 2026 Revenue: $1.1 million Q1 2026 Operating Expenses: $67.5 million Q1 2026 R&D Spend: $43.7 million +5 more

Q1 2026 Revenue

$1.1 million

Total revenue for three months ended March 31, 2026

Q1 2026 Operating Expenses

$67.5 million

Operating expenses for three months ended March 31, 2026

Q1 2026 R&D Spend

$43.7 million

Research and development expenses Q1 2026

Q1 2026 G&A Spend

$20.8 million

General and administrative expenses Q1 2026

Q1 2026 Net Loss

$60.2 million

Net loss for three months ended March 31, 2026

Cash & Securities

$1,076.2 million

Cash, cash equivalents and marketable securities as of March 31, 2026

ATM Net Proceeds

$391.4 million

Net proceeds from at-the-market offering in Q1 2026

Shares Outstanding

88,007,761 shares

Common shares outstanding as of March 31, 2026

Historical Context

5 past events · Latest: May 05

5 events

1. May 05

   Investor conferences

   24h Move

   -0.8%

   Announced May investor conference presentations with webcast access for investors.

2. Feb 27

   Earnings and updates

   24h Move

   +4.8%

   Reported 2025 results, strong cash of $903M, and key 1H 2026 milestones.

3. Feb 23

   Conference appearance

   24h Move

   +1.2%

   Planned TD Cowen healthcare conference presentation with webcast for investors.

4. Jan 09

   Clinical timeline

   24h Move

   +29.3%

   Pulled forward Phase 3 PIVOT‑006 topline data timing into 1H 2026.

5. Jan 06

   Conference appearance

   24h Move

   +0.8%

   Announced presentation at J.P. Morgan Healthcare Conference with webcast replay.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intravesical, non-muscle invasive bladder cancer, bcg-unresponsive, spatial transcriptomic profiling, +2 more

6 terms

intravesical medical

"Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed..."

Intravesical describes a medical treatment or procedure where a drug or therapy is placed directly into the bladder through a catheter rather than taken by mouth or injected into the bloodstream. For investors, it signals a focused delivery method that can increase local effectiveness and reduce whole‑body side effects, often affecting a product’s clinical value, patient convenience, regulatory path, and market niche — like watering a plant at its roots instead of spraying its leaves.

non-muscle invasive bladder cancer medical

"Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer"

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

bcg-unresponsive medical

"High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer"

BCG-unresponsive describes a situation in which a patient’s bladder cancer does not shrink or returns despite receiving an adequate course of BCG, a common vaccine-based intravesical treatment used to stimulate the immune system in the bladder. For investors this matters because it defines a group of patients who need alternative therapies or procedures, shaping clinical trial eligibility, regulatory pathways, and the potential market for new drugs; think of it like weeds that resist the usual weed killer and require a different product.

spatial transcriptomic profiling medical

"Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC..."

Spatial transcriptomic profiling maps which genes are active and where they are located within a tissue sample, combining gene activity measurements with their physical position much like a weather map shows temperatures across a city. Investors care because this method helps drug developers and diagnostics companies identify precise disease targets and biomarkers, which can speed up R&D, improve success rates, and create more valuable, differentiated products.

tumor microenvironment medical

"Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC..."

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

gene therapies medical

"BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies"

Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

-Visit CG Oncology at booth #3051-

DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gathering of urologists and urologic professionals, showcasing the latest advances in urologic medicine, clinical research and patient care.

First Results from CORE-008 Cohort CX
Title: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

• Poster Presentation May 15, 2026, 3:30 – 5:30 PM ET
• Podium Presentation at the SUO 2026 Annual Meeting at the AUA May 16, 2026, 4:25–4:30 PM ET

Additionally, the grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA. This Fellowship is designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). Details of the presentations are below:

• Grant Recipient Taylor A. Goodstein, MD Presents: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies
  May 16, 4:45 PM-4:50 PM ET

• Grant Recipient Saum B. Ghodoussipour, MD Presents : Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer
  May 16, 4:50 PM-4:55 PM ET

Attendees of AUA 2026 are encouraged to visit CG Oncology at booth #3051 to learn more about the company’s clinical development program and its commitment to advancing innovative therapies for patients with bladder cancer.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com. 

Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com 

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CG Oncology (NASDAQ: CGON) presenting at the AUA 2026 Annual Meeting?

CG Oncology will present first results from the CORE-008 Cohort CX Phase 2 trial in high-risk BCG-exposed and BCG-unresponsive NMIBC. According to CG Oncology, this study evaluates intravesical cretostimogene grenadenorepvec with gemcitabine in non-muscle invasive bladder cancer.

When and where will CG Oncology present CORE-008 Phase 2 data at AUA 2026?

CORE-008 data will be shared in a poster session on May 15, 2026, 3:30–5:30 PM ET and a podium presentation on May 16, 2026, 4:25–4:30 PM ET. According to CG Oncology, both sessions occur during the SUO 2026 Annual Meeting at AUA.

What is the CORE-008 Phase 2 trial that CG Oncology is discussing at AUA 2026?

CORE-008 is a Phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. According to CG Oncology, it assesses combination therapy delivered directly into the bladder (intravesical).

How is CG Oncology involved with NMIBC research fellowships presented at AUA 2026?

CG Oncology sponsors the annual CG-SUO-CTC NMIBC Research Fellowship, whose grant recipients present at SUO 2026. According to CG Oncology, the fellowship supports clinical cancer researchers focused on understanding and treating non-muscle invasive bladder cancer (NMIBC).

Which CG-SUO-CTC NMIBC fellowship projects linked to CG Oncology will be shown at AUA 2026?

Fellow Taylor A. Goodstein, MD will present on spatial transcriptomic profiling in BCG-unresponsive NMIBC treated with novel intravesical gene therapies, and Saum B. Ghodoussipour, MD will present on dynamic intra-tumor heterogeneity. According to CG Oncology, both talks occur May 16, 2026.

Where can attendees meet CG Oncology at the AUA 2026 Annual Meeting?

AUA 2026 attendees can visit CG Oncology at booth #3051. According to CG Oncology, visitors can learn more about the company’s clinical development program and its commitment to advancing innovative therapies for patients with non-muscle invasive bladder cancer.